ライフサイエンスコーパス: breath test

1 ociated with methane production (measured by breath tests).

2 investigated by MRI and (13)C-lactose-ureide breath test.

3 pylori status was confirmed by a (13)C-urea breath test.

4 ding both scintigraphy and C13-octanoic acid breath test.

5 Eradication was confirmed with urea breath test.

6 olids was analysed by the [13C]octanoic acid breath test.

7 ylori eradication was determined by 13C-urea breath test.

8 ere screened for H. pylori with the 13C-urea breath test.

9 was assessed by the carbon-13-labelled urea breath test.

10 s were evaluated using the 13C-octanoic acid breath test.

11 ltaneous scintigraphy and [13C]octanoic acid breath test.

12 ireless motility capsules and nonradioactive breath tests.

13 cterial overgrowth, the simplest of which is breath tests.

14 The average breath test (14)CO(2) area under the curves were 1.9- an

15 14C urea breath test (14C-UBT) was performed 4 weeks after the er

16 Cure was determined by using the urea breath test 2 months after antimicrobial treatment.

17 Eradication was assessed by urea breath test 6-8 weeks after randomisation.

18 Development of stable-isotope breath tests, allowing in situ phenotype analyses, may e

19 In both groups, a lactose hydrogen breath test and a lactose tolerance test were performed

20 n was found in 22% of patients by means of a breath test and could not be predicted by gastrointestin

21 Lactose hydrogen breath test and lactose tolerance test were positive in

22 HP eradication was confirmed using urease breath test and stool antigen test.

23 We assessed GE with a (13)C-spirulina breath test and symptoms in 78 participants with type 1

24 ed with the use of the lactose [(13)C]ureide breath test and the adrenal response to CRF was assessed

25 n CYP3A4 activity using the 14C-erythromycin breath test and the traditional phenotypic trait measure

26 prove eradication rather than just the urea breath test and to use intent-to-treat rather than asses

27 Patients were also tested by a urea breath test and were subjected to esophagogastroduodenos

28 g fat), and gastric emptying ((13)C-acetate breath test) and blood glucose, plasma insulin, C-peptid

29 ying was assessed by a labeled octanoic acid breath test, and concentrations of gastrointestinal horm

30 or interstitial lung disease, two diagnostic breathing tests, and cigarette smoking history.

31 We used the 13C urea breath test as the confirmatory method for H. pylori sta

32 Different breath tests assay, (1) exhaled antigen 85, (2) mycobact

33 nd 6 months and with carbon-13-labelled urea breath test at 3 months.

34 asive techniques, such as breath tests (urea breath test), blood pressure measurements using a sphygm

35 ng diagnostic approaches, reporter phage and breath tests, both of which assay mycobacterial metaboli

36 P1A2 activity, the [(13)C 3-methyl] caffeine breath test (CBT), might be clinically useful in identif

37 We tested (13)C-urea breath test-characterized serum samples from 109 U.S. pa

38 hypothesis proves correct, phage assays and breath tests could become important surrogate markers in

39 Increasing breath test "duration" (samples over 4, 5, or 6 hours) y

40 imated using the carbon-14 [14C]erythromycin breath test (ERMBT) before surgery and 24, 48, and 72 hr

41 easing driver's age and was greater when the breath test for alcohol was positive.

42 rs or older who were interviewed and given a breath test for estimated BAC during roadside surveys th

43 [13C]Octanoic acid breath test for gastric emptying of solids requires furt

44 bitors for 2 weeks before receiving the urea breath test for H. pylori infection.

45 ow the development and evaluation of a rapid breath test for isoniazid (INH)-sensitive TB based on de

46 covered include improving the specificity of breath tests for bacterial overgrowth; small bowel enter

47 They underwent a 14C-urea breath test, H. pylori serology, fasting gastrin, gastri

48 Thus, breath test half emptying time (t1/2) minus 66 minutes w

49 electrogastrography, and the C octanoid acid breath test have been used in the study of normal and ab

50 Both reporter phage and breath tests have promise as early markers to determine

51 levels of H2 and CH4 in a positive hydrogen breath test (HBT) was demonstrated.

52 eted gas, a prevalence of abnormal lactulose breath test in 84% of IBS patients, and a 75% improvemen

53 easured with the [14C N-methyl] erythromycin breath test in each subject.

54 ate the accuracy and reproducibility of this breath test in healthy subjects.

55 cin (a Pgp substrate) using the erythromycin breath test in mice proficient and deficient of mdr1 dru

56 ]fatty acids, exogenous lipid oxidation with breath-test/indirect calorimetry, and fecal excretion.

57 tility and specificity of lactulose hydrogen breath testing is yet again being called into question.

58 tility and specificity of lactulose hydrogen breath testing is yet again questioned and further data

59 earance (Cl), MEGX concentration, methionine breath test (MBT), galactose elimination capacity (GEC),

60 Follow-up 14C-urea breath tests of all 102 patients who eradicated H. pylor

61 a GLP-1 concentrations and gastric emptying (breath test) over 240 min.

62 Newer imaging methods and breath tests require further validation, but appear prom

63 H. pylori was not eradicated had a negative breath test result while receiving lansoprazole.

64 The proportions of patients whose breath test results were positive after completion of la

65 Consecutively 13C urea breath tests results were extracted from the files over

66 ues were observed in some subjects, repeated breath tests showed a high degree of reproducibility wit

67 All participants had (13)C-spirulina GE breath test T1/2 values of 79 minutes or more (with 89.8

68 Mice were given breath tests to analyze GE of solids.

69 Participants with a positive (13)C-urea breath test (UBT) 6 to 8 weeks posttreatment were offere

70 H. pylori colonization by using the 13C-urea breath test (UBT) and were asked to provide fecal sample

71 The 13C urea breath test (UBT) has been shown to be an extremely accu

72 cluded 154 patients with positive (13)C-urea breath test (UBT).

73 of H. pylori infection by serology and urea breath test (UBT).

74 Noninvasive techniques, such as breath tests (urea breath test), blood pressure measurem

75 Previous work suggested that a breath test using 13C accurately measures gastric emptyi

76 < 150, underwent a gastric emptying test by breath test using 13C octanoic acid coupled to a solid m

77 Carbon labeled urea breath tests usually entail a two point sampling with a

78 The erythromycin breath test was evaluated to determine hepatic activity

79 The erythromycin breath test was next administered to mdr1a(-/-) and mdr1

80 The urea breath test was repeated at 28 days.

81 The breath test was repeated three times within a 3-week per

82 The erythromycin breath test was used to measure CYP3A4 activity in vivo

83 ri prevalence, as determined by the 13C-urea breath test, was 69%, and prevalence increased from 53%

84 Parameters from scintigraphy and breath test were not correlated significantly.

85 stological assessment, rapid urease test and breath test were performed before and eight weeks after

86 s who tested positive for H pylori by a urea breath test were randomly assigned by a central computer

87 alprotectin, thyroid tests, celiac serology, breath tests were more frequently suggested in IBS-C and

88 diagnosed on the basis of (13)C-labeled urea breath tests) were enrolled in a household-randomized, u

89 y, all patients underwent a gastric emptying breath test with assessment of postprandial severity of